Compare Northrop Grumman Corporation (NOC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Northrop Grumman (NOC) trades at $484.48, up 0.28% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $7.68 exceeding expectations by 12.6%. Recent news highlights the loss of a $20B Navy fighter contract to Boeing, creating near-term headwinds. Technical indicators show oversold conditions with RSI at 16.17, while the stock trades below key resistance at $484.

NOC presents a compelling value opportunity with a 15.05 P/E ratio and 26.96% ROE, supported by a 54% analyst buy rating and $615.75 price target. Risks include competitive contract losses and defense budget uncertainties, but the company's $104.7B backlog and dividend growth provide stability. The current technical weakness may offer entry points for long-term investors seeking defense exposure.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.